Open AccessP1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG‐TERM EXTENSION STUDY
Author(s) -
Grace R. F.,
Glenthøj A.,
Barcellini W.,
Verhovsek M.,
Rothman J. A.,
Morado Arias M.,
Layton D. M.,
Andres O.,
Galactéros F.,
Beers E. J.,
Onodera K.,
Viprakasit V.,
Chonat S.,
Porter J. B.,
Judge M. P.,
Kosinski P. A.,
Hawkins P.,
Gheuens S.,
Xu R.,
McGee B.,
Bey V.,
AlSamkari H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000849036.11558.e5
Subject(s) - medicine , clinical endpoint , hemoglobin , hemolysis , pyruvate kinase deficiency , placebo , anemia , blood transfusion , surgery , randomized controlled trial , gastroenterology , pyruvate kinase , metabolism , alternative medicine , glycolysis , pathology